Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

427 $15,315 $47,472 $27,304

Royalties 3,956 - 3,956 -

License, collaboration

and other 22,237 10,093 23,003 13,354

Total revenues 51,620 25,408 74,431 40,658

Costs and expenses:

Cost of sales 4,351 2,392 7,734 3,949

Research and development 17,151 28,799 34,396 55,977

Selling, general and

administrative 35,342 46,504 67,792 88,952

Restructuring charges - 5,367 (7) 5,367

Total costs and expenses 56,844 83,062 109,915 154,245

Loss from operations (5,224) (57,654) (35,484) (113,587)

Other income (expense), net:

Interest and other income,

net 6,333 3,222 7,868 7,265

Interest expense (3,661) (3,166) (6,835) (6,332)

Total other income (expense),

net 2,672 56 1,033 933

Loss before income taxes (2,552) (57,598) (34,451) (112,654)

Income tax provision 1,742 - 1,742 -

Net loss $(4,294) $(57,598) $(36,193) $(112,654)

Basic and diluted net

loss per share $(0.07) $(0.97) $(0.60) $(1.91)

Shares used in computing

basic and diluted net

loss per share 60,856 59,223 60,706 59,089

Reconciliation of GAAP Items

to Non-GAAP Items:

Net loss, GAAP as reported $(4,294) $(57,598) $(36,193) $(112,654)

Adjustments:

Non-recurring stock-based

compensation charges - 13,186 - 13,186

Restructuring ch
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  New Jersey Health Foundation, a not-for-profit organization ... of New Jersey , has committed ... announced James M. Golubieski , president. ... program, an additional $500,000 will be available for awards ... research projects that demonstrate exciting potential and may lead ...
(Date:3/30/2015)... 2015 CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , announced ... has approved the Company,s application to conduct a Phase ... (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... CARDIFF, UK, and BELLINGHAM, Washington, USA (PRWEB) March 29, ... energy projects in Europe and the United States and ... programme highlights planned for SPIE Optics + Optoelectronics ... will feature over 700 technical presentations in 17 conferences ... international society for optics and photonics , the event ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3
... ... of Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) October 2, 2009 ... (SLV) series specifically for biotech and specialty pharma companies. The new series includes Situational ...
... ... Orange County Emerging Growth Awards, recognizing companies headquartered in Orange County that have reached ... 12 months and that have made a positive impact on the local economy. ... Orange County, CA ...
... a plane the consequences can be fatal, not only for ... the aircraft fuselage, causing stresses in the material which can ... skin will detect such damage at an early stage and ... they don,t need any cables or batteries. They draw their ...
Cached Biology Technology:Perceptum Group Announces New Situational Leadership V Series 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 2Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 3Southern California Venture Network Announces Recipients of the 2009 Orange County Emerging Growth Awards 4Energy-autonomous sensors for aircraft 2
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... light box and the over-the-counter drug melatonin -- allows ... body clock before crossing several time zones, according to ... of Clinical Endocrinology and Metabolism. This treatment can ... a persistent condition that results from a misalignment between ...
... Not least because undifferentiated cells with features typical of ... the liver, brain, and muscles, scientists are beginning to ... organs. Researchers from the Max Planck Institute for Heart ... demonstrated, in a study published in the journal Molecular ...
... on the use of antiseptics and antibiotics in hospitals is ... bacterial infection? , Yes, argues Mark Spigelman, a visiting professor ... Infectious and Tropical Diseases at the Hebrew University of Jerusalem's ... report on the poor record of bacterial infections in patients ...
Cached Biology News:Travelers can avoid jet lag by resetting their body clocks 2Travelers can avoid jet lag by resetting their body clocks 3Forgotten by evolution? 2'Good' bacteria could save patients from infection infection by deadlier ones 2
...
...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid...
... moderate chemiluminescence efficiencies and the chemistry of ... the added benefit that they require simple ... background signal. This benefit has been exploited ... applications. These compounds can also be easily ...
Biology Products: